Ptc Therapeutics (PTCT) Net Equity Issued and Repurchased (2012 - 2020)

Ptc Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $9.1 million for Q3 2020.

• In Q3 2020, Net Equity Issued and Repurchased fell 90.83% year-over-year to $9.1 million; the TTM figure through Dec 2020 stood at $28.1 million (down 91.32% YoY), while the FY2020 annual figure was $28.1 million, down 91.32% from the prior year.
• Net Equity Issued and Repurchased for Q3 2020 stood at $9.1 million, up from $5.4 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $224.4 million in Q1 2019, with the low at -$506000.0 in Q4 2019.
• The 3-year median for Net Equity Issued and Repurchased is $2.8 million (2019), against an average of $35.2 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 243112.2% in 2019, while the deepest fall reached 50700.0% in 2019.
• Ptc Therapeutics' Net Equity Issued and Repurchased stood at $1000.0 in 2018, then slumped by 50700.0% to -$506000.0 in 2019, then surged by 1906.72% to $9.1 million in 2020.
• Business Quant data shows PTCT's Net Equity Issued and Repurchased at $9.1 million in Q3 2020, $5.4 million in Q2 2020, and $13.5 million in Q1 2020.